BB&T Securities’s Sarepta Therapeutics SRPT Stock Holding History

BB&T Securities’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$294K	Sell	3,879 -31	-0.8%	-$3.66K	﹤0.01%	1331
2019 Q2	$594K	Buy	3,910 +20	+0.5%	+$2.43K	0.01%	1025
2019 Q1	$463K	Buy	3,890 +332	+9%	+$42.7K	﹤0.01%	1115
2018 Q4	$388K	Sell	3,558 -222	-6%	-$27.8K	﹤0.01%	1077
2018 Q3	$610K	Sell	3,780 -1,010	-21%	-$138K	0.01%	997
2018 Q2	$633K	Sell	4,790 -3,205	-40%	-$302K	0.01%	978
2018 Q1	$592K	Buy	7,995 +2,286	+40%	+$152K	0.01%	953
2017 Q4	$317K	Buy	+5,709	New	+$302K	﹤0.01%	1166

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BB&T Securities's SRPT Position: Q3 2019 in Review

BB&T Securities reduced its Sarepta Therapeutics (SRPT) stake by 0.79% in Q3 2019, selling an estimated $3.66K and leaving 3,879 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

BB&T Securities first reported a position in SRPT in Q4 2017 and has held it in 8 quarters since. The position peaked at $633K in Q2 2018. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

BB&T Securities held 3,879 shares of Sarepta Therapeutics worth $294K as of Q3 2019.
BB&T Securities sold 31 Sarepta Therapeutics shares in Q3 2019, an estimated $3.66K.
Sarepta Therapeutics made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1331 holding.
BB&T Securities first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 8 quarters since.
BB&T Securities's Sarepta Therapeutics position peaked at $633K in Q2 2018.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.